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DEGENERATIVE JOINT DISEASE (DJD) OBJECTIVES 
• To assess the advantages and disadvantages of using different origin mesenchymal 
stem cells (MSCs) and compare their effectiveness in the horse with DJD. 
• To establish an own judgement of clinical use , as well as a treatment proposal.  
DJD is the most prevalent joint pathology in horses. It is a chronic, irreversible 
degenerative process, based on  progressive cartilage erosion, joint space narrowing, 
subchondral bone remodeling, marginal osteophytosis, synovitis and joint capsule 
fibrosis . 
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• Lameness 
• Thickening of  joint capsule 
• Pain on manipulation 
• Progressive loss of joint function 
• Muscle atrophy 
• Behavioural changes 
• Decrease in athletic performance 
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STEM CELLS 
DEFINITION 
A stem cell is an undifferentiated cell capable of dividing indefinitely 
and differentiate into several specialized cell types, not only 
morphologically but also functionally. Stem cells main features are : 
1. Self-renewal due to  telomerase activity 
2. Pluripotentiallity ability to differentiate into other cell types 
CLASSIFICATION 
 
 
ACCORDING TO ORIGIN: 
 
• Embryonic stem cells (ESCs): properties of self-renewal and 
pluripotency, offer the possibility of an unlimited, renewable 
source of cells that can be induced to differentiate into any cell of 
the body. 
• Adult stem cells: found within the majority of tissues.                        
MSCs hold the greatest therapeutic potential.  
• iPSC: generated from adult, terminally differentiated cells,                                                        
re-programme cells into very similar ESCs by the introduction of four 
genes (Oct4, Sox2, cMyc and Klf4). 
 
 
 
MSCs  + PRP COMBINED THERAPY 
CONCLUSIONS 
MSCs TISSUE COLLECTION AND DIFFERENTIATION IN VITRO  
Autologous MSCs are obtained 
from the individual itself. The main 
disadvantage is that their 
expansion process  takes 10 -21 
days, so the treatment start is 
delayed and difficult  as a result of 
the growth kinetic variations . In 
addition, some collection 
techniques are invasive  and  
might be not be suitable for  all  
patients.  
AUTOLOGOUS   VS  ALLOGENEIC MSCs 
ACCORDING TO  POTENTIAL DIFFERENTIATION:  
• Totipotent:  able to create an entire organism 
• Pluripotent: capable of differentiating into cells of the 3 germ lines 
(endoderm, mesoderm and ectoderm). 
• Multipotent: capable of differentiating into a limited lineages but 
also more specialised cell types 
• Unipotent: capable of differentiating into a unique cell type. 
 
Allogeneic MSCs are obtained 
from a different donor. They 
allow immediate treatment of 
acute orthopedic lesions.  Some 
security studies done in horses by 
intraarticular administration in 
healthy joints, have shown 
promising prospects due to the 
similar response to  autologous 
MSCs.  
Bone marrow (BM) and adipose tissue (AT)  have 
been the most common sources of MSCs from 
years. Nevertheless, umbilical cord  blood (UCB) as 
well as peripherial blood (PB), gum and periodontal 
ligament may be rising alternatives.  
CELL THERAPY 
MSCs  EFFECT ON CARTILAGE REPAIR 
A study of the literature makes it apparent that MSCs injected  intraarticularly do not engraft into the endogenous 
cartilage and directly affect repair. Nevertheless, they do appear to have analgesic and chondroprotective benefits 
retarding the progression of cartilage destruction by reducing inflammation.  Treatment timing seems to be a key 
factor in the degree to which MSCs modulate the progression of cartilage destruction.  
 However, recent advances in tissue engineering technologies  have allowed to create  scaffolds for regenerative 
medicine. such as HR007, which is composed of sulphated glycosaminoglycans (sGAGs) and hyaluronic acid (HA). 
HR007 scaffolds induce cell proliferation, enhance the expression of specific gen markers, induce the tissue 
production and have chemotactic effects over the MSCs 
 
       
TREATMENT/ STUDY PROPOSAL 
 A study compared the conventional regenerative 
therapies based on the use of PRP or native MSCs 
alone, with the combined treatment (MSCs + PRP) 
 The results shown that PRP enhances  MSCs 
proliferation and chondrogenic differentiation.  
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* Allogeneic MSCs  are safe even administrating more than 
a  single dose. They allow us to establish an early 
treatment without having to wait for their expansion. 
Patients age and exposure to invasive techniques 
become irrelevant. 
* BM-MSCs are characterized by a great rate of isolation, 
good regenerative behaviour, the shortest culture period 
and tri-potential differentiation capacity .  
* AT-MSCs are characterized by great inmunomodulatory 
behaviour. It would be interesting to combine with BM-
MSCs to determine possible synergistic effects. 
* PRP enhances MSCs proliferation and chondrogenic 
differentiation so it improves the regenerative results 
short (6-12weeks) and long term (6-12months) when 
combined. 
* Tissue engineering based on sGAGs  and HA might allow 
horse MSCs to engraft cartilage, decrease the expression 
of matrix degradation factors and make chondrogenic 
differentiation.  
